RxDoctor Payments DataLook up a doctor →

Jeffrey Robbins

Family · Boise, IDNPI 1669408514

Payments from drug & device makers

$8,752in general payments, 2019–2025

Across 520 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$864
  • Amgen$791
  • Lilly USA, LLC$526
  • Pfizer$468
  • Novo Nordisk$410
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$8,752100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie120$1,642
AstraZeneca38$864
Amgen(2 entities)46$791
Lilly USA, LLC35$526
Pfizer31$468
Novo Nordisk25$410
Boehringer Ingelheim11$215
Teva Pharmaceuticals USA, Inc.11$211
Novartis11$198
Antares Pharma, Inc.10$196
Corium, LLC11$183
Bayer8$177
Supernus Pharmaceuticals, Inc.12$167
Johnson & Johnson10$164
Neurocrine Biosciences, Inc.11$155
Phathom Pharmaceuticals, Inc.11$149
Shield Therapeutics Inc8$146
Takeda Pharmaceuticals U.S.A., Inc.7$146
Corcept Therapeutics7$136
E.r. Squibb & Sons, L.L.C.7$119
Dexcom, Inc.3$113
Sanofi-aventis U.S. LLC6$109
Idorsia Pharmaceuticals US Inc6$98
Mylan Specialty L.p.5$88
Axsome Therapeutics, Inc.4$81
Astellas Pharma US Inc4$79
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$69
GSK4$69
Sunovion Pharmaceuticals Inc.6$63
Nestle Healthcare Nutrition Inc.3$60
Otsuka America Pharmaceutical, Inc.3$60
Exact Sciences3$58
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$54
Medtronic1$48
Tris Pharma Inc2$44
Sanofi Pasteur Inc.2$44
Merck2$44
Kyowa Kirin, Inc.2$42
Otsuka Pharmaceutical Development & Commercialization, Inc.2$41
Sumitomo Pharma America, Inc.2$41
Genentech USA, Inc.2$33
Arbor Pharmaceuticals, Inc.2$28
Daiichi Sankyo Inc.1$25
Alnylam Pharmaceuticals Inc.1$22
Biohaven Pharmaceuticals, Inc.1$22
Tanabe Pharma America, Inc.1$20
Regeneron Healthcare Solutions, Inc.1$19
Xeris Pharmaceuticals, Inc.1$19
Viatris Specialty LLC1$18
Abbott1$17
Ultragenyx Pharmaceutical Inc.1$17
Lundbeck LLC1$16
Scilex Pharmaceuticals Inc.1$15
Mayne Pharma Commercial LLC2$15
Biohaven Pharmaceutical Holding Company Ltd.1$14
Aimmune Therapeutics, Inc.1$14
Boston Scientific1$14
Esperion Therapeutics, Inc.1$14
Azurity Pharmaceuticals, Inc.1$14
Exeltis, USA Inc.1$13

How this compares

$8,752 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$10,232
Medicare patients
50
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide46$67,587
JardianceEmpagliflozin17$14,947
Testosterone Cypionate55$5,133
Gabapentin141$4,114
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine110$3,584
Pregabalin77$3,455
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,873
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen121$2,720
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine44$2,625
Albuterol Sulfate HfaAlbuterol Sulfate85$2,488
Levothyroxine Sodium248$1,980
Hydroxychloroquine Sulfate36$1,860
Duloxetine Hcl86$1,544
Sucralfate39$1,470
Aripiprazole25$1,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$526$67,58746 claims
Boehringer IngelheimJardiance$215$14,94717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Idaho.

Other family in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →